Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal
Just days ahead of Vas Narasimhan’s jump into the CEO’s spot, Novartis has swooped in with a $170 million deal to grab ex-US rights on Spark Therapeutics’ Luxturna, the first true gene therapy to get a US approval.
The pharma giant is paying $105 million in cash and putting another $65 million on the table for near-term European regulatory milestones. Spark $ONCE also qualifies for a royalty stream on ex-US sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
